retatrutide clinical trial phase 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Lilly's triple agonist, retatrutide, delivered

Supports digestive comfort: Contains Vitamin C to support the normal function of the immune system

For marketers, this shows that even highly regulated industries can enter mainstream conversation when timing, context, and audience are aligned.

GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d

Over the last two years, GLP-1 receptor agonists have moved from specialist clinics to centre stage, increasingly being considered by general practitioners, employer health programs, and digital platforms alike

The ever-expanding popularity of GLP-1 drugs for weight loss is challenging employers to balance access and cost.